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Summary The serum CA125 level was determined by a one-step immunoradiometric assay method in patients
with lung cancer. Increased serum CA125 levels were observed in 37.8% of patients with squamous cell cancer,
in 30.0% of those with adenocarcinoma and in 60.0% of those with small call cancer. Most patients with
increased serum CA125 levels were in stages 3 or 4. Patients with pleural effusions or ascites showed high
serum CA125 levels. The survival time was significantly shorter in patients with increased serum CA125 levels
than in those within normal limits. Among patients with advanced disease (stages 3 and 4), an increased serum
CA125 level was again a poor prognostic factor (P<0.01). The existence of a pleural effusion did not
correlate with the survival time. We conclude that CA125 is a good indicator of disease extent and serum
levels correlate to the length of survival.
Owing to the recent progress in immunology, many mono-
clonal antibodies against various malignant tissues and their
products have been developed and some of them are now in
clinical use. One of these is OC125, which is obtained by
immunising mice with ovarian cancer cell lines (Bast et al.,
1981). The antigen recognised by this antibody, CA125, has
been proved to show increased serum levels in a high percen-
tage of patients with ovarian cancer and endometriosis (Bast
et al., 1983; Kabawat et al., 1983a; Baumah et al., 1987;
Fleuren et al., 1987; Takahashi et al., 1986). Recently, other
antibodies, designated 130-20 and 145-9 have been prepared
by immunising mice with the lung adenocarcinoma cell line
PC-9 (Matsuoka et al., 1987; Kunimatsu et al., 1988). These
antibodies recognise the same molecule as does OC125, but
the epitopes which are recognised are different for each
antibody. As the antibodies 13-20 and 145-9 were raised
against a pulmonary adenocarcinoma cell line, it seemed
possible that CA125 could also be a tumour marker for lung
adenocarcinoma. We examined serum CA125 levels in
patients with lung cancer by one-step immunoradiometric
assay, and found, contrary to the first hypothesis, that this
antigen was not specific only to lung adenocarcinoma but it
also reflected the extent of lung cancers of various types
including adenocarcinoma and their prognosis.
Materials and methods
Assay kit
The assay kit for CA125 was kindly donated by the Daiichi
Radioisotope Laboratory (Tokyo, Japan). The assay method
was a one-step immunoradiometric assay using '25I-labelled
antibody 130-20 solution and latex beads coated with anti-
body 145-9. The correlation between CA125 levels measured
by the current method and those measured by the conven-
tional method (ELSA CA125 kit, CIS, Saclay, France) was
y = 0.886x + 2.405, r = 0.931, n = 477.
Subjects
Blood samples were collected from 752 normal subjects in
our institute and related hospitals. Serum samples obtained
from 95 untreated patients with lung cancer and 43 patients
with benign lung diseases from 1982 and 1987 were stored at
-20°C until examination.
Statistical analysis
Differences of the CA125 level by sex and age in normal
subjects were estimated by Student's t test. The proportions
of patients in various groups with the elevated marker were
estimated by the x2 test. The survival was calculated from the
time of blood sampling. The survival rates were estimated by
the Kaplan-Meier method and were compared using the
generalised Wilcoxon test.
Results
Normal range ofserum CA125 using the one-step
immunoradiometric assay kit
CA125 levels ranged from 2.7 to 87.6 Uml' (mean ± s.d.
15.3 ± 9.9). There existed a significant difference between the
serum CA125 level of males and females. These were 9.6 +
5.1 U ml-' and 17.3 ± 10.5 U ml-', respectively (P<0.01)
(Figure 1). Among the females, there existed a significant
difference between the serum CA125 levels of younger sub-
jects (younger than 50) and older subjects (P<0.01). This
may be due to the changes of menstrual activity around the
age of 50, as the serum CA125 levels were higher in menstru-
ating women and lower after menopause (Table I).
According to these results, we determined the cut-off
values as 20 U ml ' for males and 38 U ml ' for females.
Cut off value Cut off value
for mate for female
fGMale
50 Female
--Male
X -Female
CD
0
E
M loo. 4-10
0
.0
E
Z 50
100%
_
C) 0.
o
50 0
to
'U
E
O
20 30 40 50 60 70 80 90
Serum CA125 level (U ml')
Figure 1 Serum CA125 levels of normal subjects. The cut-off
value for males is 20 U ml-' and that for females is 38 U ml '.
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Table I Serum CA125 levels of normal females
Mean
n (Uml') s.d. Range
Oestrogenic phase 20 16.8 5.9 8.1-30.4
Ovulatory phase 9 10.9 2.4 8.2-14.9
Luteal phase 22 16.2 5.6 9.5-34.0
Menstrual phase 16 24.2 9.0 13.3-50.9
Menopause 16 12.1 3.4 6.9-18.0
Serum CA125 levels ofpatients with lung diseases
Ninety-five patients with lung cancer and 43 patients with
benign lung diseases were examined. The stages of lung cancer
were decided according to TNM classification of the Union
Internationale Contre le Cancer. The clinical features are
summarised in Tables II and III. Increased serum levels of
CA125 were observed in 14 out of 27 patients with squamous
cell cancer (37.8%), in 14 out of 35 with adenocarcinoma
(30.0%) and in nine out of 15 with small cell cancer (60.0%).
These values were significant compared with that of normal
subjects (P<0.01). Serum CA125 levels remained below the
cut-off level in the patients with large cell lung cancer (Figure
2). Like other tumour markers, the serum CA125 level was
high in the advanced stages of the disease. There was only
one early-stage patient who showed an elevated serum
CA125 level and he developed brain metastases 7 months
later. It was found that most patients with pleural effusions
or ascites had increased serum CA125 levels (11 out of 12),
but 42.9% of patients in stages 3 and 4 without pleural
effusions or ascites still had increased serum CA125 levels
(squamous cell carcinoma 41.7%, adenocarcinoma 46.2%
and small cell carcinoma 66.7%).
In contrast to lung cancer, only five out of43 patients with
benign lung diseases had increased serum CA125 levels
(11.6%, normal vs benign lung diseases; P<0.05), and the
degree of increase was slight (mean ± s.d.; 12.7 + 13.6). In-
creased levels were found in one patient with sarcoidosis,
three with primary interstitial pneumonitis, and one with
silicosis, and pleural effusions was not present in these
patients.
Table II Clinical features ofpatients with lung cancer
Type oflung cancer
SCC Adeno SCLC LCLC
Total cases 37 35 15 8
Male 35 22 14 7
Female 2 13 1 1
Age median 71 62 62 57
Range 50-79 25-79 49-80 33-75
Stage I 9 7 1 1
2 2 6 1 0
3 20 10 7 1
4 6 12 6 6
With pleural effusion or 2 9 1 0
ascites
SCC, squamous cell carcinoma; adeno, adenocarcinoma; SCLC,
small cell lung cancer; LCLC, large cell lung cancer.
Table III Benign lung diseases
Number of
Diagnosis patients
Sarcoidosis 10
Pulmonary tuberculosis 9
Interstitial pneumonitis 4
Pulmonary fibrosis 5
Silicosis 1
Asthma I
Wegener's granuloma I
Diffuse panbronchiolitis 2
Bronchitis or pneumonia 5
Bronchiectasis 3
Abscess I
Chronic obstructive lung disease I
Relationship ofCA125 level toprognosis
We compared the survival rate ofpatients with respect to the
CA125 level, the presence of pleural effusion, staging, and
histology. As shown in Figure 3, the survival curve of
CA125 + (serum CA125 level>cut-off level) patients was
markedly worse than that of CA125 - (serum CA125
level 7 cut-off level) patients. As almost all CA125 + patients
were in the advanced stages, a further evaluation was per-
formed comparing stage 3 and 4 patients. Among the
patients with stage 3 and 4 lung cancer, the survival curve of
CA125 + cases was significantly worse, and no CA125 +
case survived beyond 2 years. The overall survival curve in
stage 4 cancer was worse than in stage 3 cancer, but survival
beyond 1.5 years did not differ significantly (Figure 4). The
existence of a pleural effusion did not affect the survival rate
(Figure 5; P<0.05). Although squamous cell cancer was
associated with better survival than small cell cancer
(P<0.05), the other types of lung cancer did not differ
significantly from each other (Figure 6).
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Figure 2 Serum CA125 levels of patients with lung diseases.
Closed circles indicate males and open circles indicate females.
Large circles indicate patients with pleural effusion or ascites.
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Figure 3 Survival curves of patients with lung cancer depended
on their serum CA125 level. a, all cases examined (CA125 + vs
CA125-, P<0.01). b, patients in stages 3 and 4 (CA125 + vs
CA125-, P<0.05).678 Y. KIMURA et al.
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Figure 4 Survival curves of patients with lung cancer depended
on their stages (stage 4 vs stage 3, P<0.05).
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Figure 5 Survival curves of patients with stage 3 and 4 lung
cancer with or without pleural effusion (effusion + vs effusion -,
P>0.05).
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Figure 6 Survival curves of patients with stage 3 and 4 lung
cancer based on its histological diagnosis (squamous cell lung
cancer vs small cell lung cancer, P<0.05).
Discussion
We evaluated the serum CA125 levels of patients with lung
cancer using a one-step immunoradiometric assay. Although
previous reports have revealed close association between
ovarian tumours and serum CA125 levels, there have been
few papers which show the significance of CA125 in lung
cancer. In this study, by setting different cut-off values for
males and females, we found a high positive rate in advanced
lung cancer. Furthermore, increased serum CA125 levels
were observed in patients with a poor prognosis.
It is notable that 38% of patients with lung cancer had
elevated serum CA125 levels, and that if one looks at stage 3
and 4 patients, the marker was present in 49% of those with
squamous cell carcinoma (42% of those without effusions),
63% of those with adenocarcinoma (46% of those without
effusions) and 69% of those with small call carcinoma (67%
of those without effusions). CA125 is an antigen of ovarian
adenocarcinoma cells, and recently it has been shown to exist
on the ectodermal cells of the peritoneum and pleura
(Kabawat et al., 1983b). This may explain why most patients
with pleural effusions or ascites had increased serum CA125
levels, but the marker was still present in relatively high
percent of patients without effusions (42% of those with
squamous cell carcinoma, 46% of those with adenocarcin-
oma and 67% of those with small cell carcinoma). Immuno-
histological examination demonstrated CA125 antigen in the
lung adenocarcinoma but failed to demonstrate in the other
types of lung cancer (Mutsuoka et al., 1987). Although the
site of production of CA125 in advanced stages is not
clarified, we consider that those patients who were CA125 +
without pleural effusions may have had microscopic invasion
of the pleura and the serum level of this marker correlate to
the stage of the disease. The cell type variations may be the
area for a further study.
We found that an increased serum CA125 level indicated a
bad prognostic factor for lung cancer. As CA125 + patients
were more often stage 4 and more often had small cell
cancer, the survival curves were compared between stages 3
and 4, among histological types, and between patients with
and without pleural effusion. Although there were some
differences between stages 3 and 4 and between squamous
cell and small cell cancer, the CA125 levels (positive or not)
was best correlated with survival time.
We conclude that CA125 is a good indicator of disease
extent and correlates with the prognosis.
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